J&J Raises FY26 Outlook Following Positive Q2
Johnson and Johnson (J&J) has achieved Q2 revenues totalling around $25.3bn, representing a year-over-year (YoY) uptick of 6.6%, with the company's medtech division, J&J MedTech, accounting for more than a third of the total. J&J MedTech achieved revenues of around $8.93bn